<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03914495</url>
  </required_header>
  <id_info>
    <org_study_id>1312439</org_study_id>
    <nct_id>NCT03914495</nct_id>
  </id_info>
  <brief_title>The Role of Microbiome Reprogramming on Liver Fat Accumulation</brief_title>
  <acronym>MILE</acronym>
  <official_title>The Role of Microbiome Reprogramming on Liver Fat Accumulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Translational Research Institute for Metabolism and Diabetes, Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Translational Research Institute for Metabolism and Diabetes, Florida</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether reprogramming the microbiome via soluble
      fiber supplementation will decrease liver fat in obese individuals.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute Change in Liver Fat</measure>
    <time_frame>28 days</time_frame>
    <description>Liver fat changes will be assessed by MRI-PDFF</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive powdered maltodextrin to provide equivalent calories and macronutrients without any fiber.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive inulin, 10 grams TID for 28 days with titration as follows: 10 grams QD for 3 days, 20 grams BID for 4 days with the remaining 21 days at 10 g TID.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Inulin</intervention_name>
    <description>Powdered inulin will be provided in pre-weighed portions for consumption in a 1 week titration to reduce GI side effects with a 21 day intervention at full dose.</description>
    <arm_group_label>Inulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Powdered maltodextrin will be provided in pre-weighed portions for consumption in a 1 week titration with a 21 day intervention at full dose.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 35-65 years

          2. Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) 5%-30% (+0.5%)

          3. Liver stiffness &lt;3.5 kPa by Magnetic Resonance Elastography (MRE)

          4. Body mass index (BMI) 27.5-45 kg/m2

          5. Weight stable (weight change of no more than 3 kg +0.5 kg) during the 6 months prior
             to enrollment

          6. For individuals with type 2 diabetes: HbA1c ≥6.5 - &lt;9.5%. If taking allowable diabetes
             medications, HbA1c can be below 6.5%.

          7. Fasting triglycerides 400 mg/dL (4.5 mmol/L)

          8. Able to speak and understand written and spoken English

          9. Understands the procedures and agrees to participate by giving written informed
             consent

         10. Willing and able to comply with scheduled study days, laboratory tests, and other
             study procedures

        Exclusion Criteria:

        Acute or chronic medical conditions or medication that would contraindicate the
        participation in the research testing or could potentially affect metabolic function
        including, but not limited to:

          1. Diagnosis of type 1 diabetes mellitus

          2. Insulin use

          3. Change within 3 months of screening of any medication used to treat insulin resistance
             or type 2 diabetes

          4. History of regular alcohol consumption exceeding 14 drinks/week for females or 21
             drinks/week for males within the previous 6 months (1 drink = 5 ounces [150 mL] of
             wine, 12 ounces [360 mL] of beer, or 1.5 ounces [45 mL] of hard liquor)

          5. A total score of 8 on the Alcohol Use Disorders Identification Test (AUDIT)
             questionnaire, indicating harmful or hazardous alcohol consumption

          6. Clinical evidence of hepatic decompensation, including, but not limited to esophageal
             varices, ascites, or hepatic encephalopathy

          7. Evidence of other forms of chronic liver disease (including laboratory tests and
             confirmed with a single repeat, if needed):

               -  Hepatitis B virus: defined by presence of hepatitis B surface antigen

               -  Hepatitis C virus: As defined by a clinical history of previous diagnosis of
                  Hepatitis C (treated or untreated) or a positive Hepatitis C antibody.

               -  Known diagnosis of primary biliary cirrhosis, primary sclerosing cholangitis,
                  autoimmune hepatitis, or overlap syndrome

               -  Alcoholic liver disease

               -  Known diagnosis of hemochromatosis

               -  Prior known drug-induced liver injury

               -  Known or suspected hepatocellular carcinoma or other liver cancer

               -  History of liver transplant, current placement on a liver transplant list, or
                  current model of end-stage liver disease (MELD) score &gt;12

               -  Histological presence of cirrhosis on a prior biopsy

          8. Bleeding disorders

          9. Acute or chronic infections

         10. Severe asthma or chronic obstructive pulmonary disease

         11. Renal insufficiency or nephritis

         12. Thyroid dysfunction (suppressed TSH, elevated TSH &lt;10 µIU/ml if symptomatic or
             elevated TSH &gt;10 µIU/ml if asymptomatic)

         13. Uncontrolled hypertension (BP &gt;160 mmHg systolic or &gt;100 mmHg diastolic)

         14. Prior or planned bariatric surgery

         15. Gastrointestinal disorders including: inflammatory bowel disease or malabsorption,
             swallowing disorders, suspected or known strictures, fistulas or
             physiological/mechanical GI obstruction, history of gastrointestinal surgery, Crohn's
             disease or diverticulitis.

         16. Participants with intolerance to soluble fiber, sucralose or erythritol.

         17. A positive urine drug test for illicit drugs

         18. History of major depression within &lt;5 years from screening or which, in the opinion of
             a medical investigator, will impact the participant's ability to complete the study.

         19. History of eating disorders

         20. History of Cushing's disease or syndrome

         21. Untreated or inadequately controlled hypo- or hyperthyroidism

         22. Active rheumatoid arthritis or other inflammatory rheumatic disorder

         23. Pregnant or nursing females or females less than 6 months postpartum from the
             scheduled date of collection

         24. Nicotine use within the past 3 months

         25. Had major surgery within 4 weeks prior to Screening.

         26. Anemia (hemoglobin &lt;12 g/dl in men, &lt;11 g/dl in women) during screening

         27. Participation in studies involving investigational drug(s) within 30 days prior to
             Screening

         28. History or presence of cardiovascular disease (unstable angina, myocardial infarction
             or coronary revascularization within 6 months, presence of cardiac pacemaker,
             implanted cardiac defibrillator)

         29. Human Immunodeficiency Virus (HIV) infection defined as: previous diagnosis of HIV
             infection, history of positive screening or quantitative HIV testing; positive HIV
             screen

         30. Any malignancy not considered cured, except basal cell carcinoma and squamous cell
             carcinoma of the skin (a participant is considered cured if there has been no evidence
             of cancer recurrence in the previous 5 years)

         31. Use of drugs historically associated with non-alcoholic fatty liver disease (NAFLD)
             for 1 month in the previous year prior to Screening; examples include: amiodarone,
             methotrexate, systemic glucocorticoids, tetracyclines, tamoxifen, estrogens at doses
             greater than those used for hormone replacement, anabolic steroids, valproic acid,
             other known hepatotoxins

         32. Participants who fulfill any of the contraindications for MRI; examples include metal
             implants, devices, paramagnetic objects contained within the body and excessive or
             metal-containing tattoos

         33. Unable to participate in MR assessments due to physical limitations or equipment
             tolerances (e.g., MRI bore size and 500-pound weight limit) based on Investigator's
             judgment at screening

         34. Any person with history of severe claustrophobia or unable to lie still within the
             environment of the MRI scanner or unable maintain a breath hold for the required
             period to acquire images without mild sedation/treatment with an anxiolytic

         35. Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more
             within 56 days prior to Screening (participants may not donate blood any time during
             the study, through the final study day)

         36. Presence of any condition that, in the opinion of the Investigator, compromises
             participant safety or data integrity or the participant's ability to complete study
             days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Corbin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruitment Department</last_name>
    <phone>407-303-7100</phone>
    <email>tri@adventhealth.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Research Institute for Metabolism and Diabetes</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Recruitment Department</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tri-md.org</url>
    <description>Webpage for Translational Research Institute for Metabolism and Diabetes</description>
  </link>
  <reference>
    <citation>Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1):123-133. doi: 10.1002/hep.29466. Epub 2017 Dec 1. Review.</citation>
    <PMID>28802062</PMID>
  </reference>
  <reference>
    <citation>Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA. 2015 Jun 9;313(22):2263-73. doi: 10.1001/jama.2015.5370. Review. Erratum in: JAMA. 2015 Oct 13;314(14):1521.</citation>
    <PMID>26057287</PMID>
  </reference>
  <reference>
    <citation>Cohen JC, Horton JD, Hobbs HH. Human fatty liver disease: old questions and new insights. Science. 2011 Jun 24;332(6037):1519-23. doi: 10.1126/science.1204265. Review.</citation>
    <PMID>21700865</PMID>
  </reference>
  <reference>
    <citation>Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019 Apr;7(4):313-324. doi: 10.1016/S2213-8587(18)30154-2. Epub 2018 Aug 30. Review.</citation>
    <PMID>30174213</PMID>
  </reference>
  <reference>
    <citation>Caputo T, Gilardi F, Desvergne B. From chronic overnutrition to metaflammation and insulin resistance: adipose tissue and liver contributions. FEBS Lett. 2017 Oct;591(19):3061-3088. doi: 10.1002/1873-3468.12742. Epub 2017 Jul 25. Review.</citation>
    <PMID>28677122</PMID>
  </reference>
  <reference>
    <citation>Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. doi: 10.1038/nrgastro.2017.109. Epub 2017 Sep 20. Review.</citation>
    <PMID>28930295</PMID>
  </reference>
  <reference>
    <citation>Valbusa F, Agnoletti D, Scala L, Grillo C, Arduini P, Bonapace S, Calabria S, Scaturro G, Mantovani A, Zoppini G, Turcato E, Maggioni AP, Arcaro G, Targher G. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure. Int J Cardiol. 2018 Aug 15;265:162-168. doi: 10.1016/j.ijcard.2018.04.129. Epub 2018 May 2.</citation>
    <PMID>29739707</PMID>
  </reference>
  <reference>
    <citation>Adams LA, Harmsen S, St Sauver JL, Charatcharoenwitthaya P, Enders FB, Therneau T, Angulo P. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am J Gastroenterol. 2010 Jul;105(7):1567-73. doi: 10.1038/ajg.2010.18. Epub 2010 Feb 9.</citation>
    <PMID>20145609</PMID>
  </reference>
  <reference>
    <citation>Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci U S A. 2009 Sep 8;106(36):15430-5. doi: 10.1073/pnas.0904944106. Epub 2009 Aug 24.</citation>
    <PMID>19706383</PMID>
  </reference>
  <reference>
    <citation>Lonardo A, Sookoian S, Pirola CJ, Targher G. Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 2016 Aug;65(8):1136-50. doi: 10.1016/j.metabol.2015.09.017. Epub 2015 Sep 25. Review.</citation>
    <PMID>26477269</PMID>
  </reference>
  <reference>
    <citation>Loomba R, Sanyal AJ, Kowdley KV, Terrault N, Chalasani NP, Abdelmalek MF, McCullough AJ, Shringarpure R, Ferguson B, Lee L, Chen J, Liberman A, Shapiro D, Neuschwander-Tetri BA. Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis. Gastroenterology. 2019 Jan;156(1):88-95.e5. doi: 10.1053/j.gastro.2018.09.021. Epub 2018 Sep 15.</citation>
    <PMID>30222962</PMID>
  </reference>
  <reference>
    <citation>Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, Harrison SA, Brunt EM, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018 Jan;67(1):328-357. doi: 10.1002/hep.29367. Epub 2017 Sep 29. Review.</citation>
    <PMID>28714183</PMID>
  </reference>
  <reference>
    <citation>Dumas ME, Barton RH, Toye A, Cloarec O, Blancher C, Rothwell A, Fearnside J, Tatoud R, Blanc V, Lindon JC, Mitchell SC, Holmes E, McCarthy MI, Scott J, Gauguier D, Nicholson JK. Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12511-6. Epub 2006 Aug 8.</citation>
    <PMID>16895997</PMID>
  </reference>
  <reference>
    <citation>Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017 May 8;7(1):1529. doi: 10.1038/s41598-017-01751-y.</citation>
    <PMID>28484247</PMID>
  </reference>
  <reference>
    <citation>Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gérard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12):1787-94. doi: 10.1136/gutjnl-2012-303816. Epub 2012 Nov 29.</citation>
    <PMID>23197411</PMID>
  </reference>
  <reference>
    <citation>Kaden-Volynets V, Basic M, Neumann U, Pretz D, Rings A, Bleich A, Bischoff SC. Lack of liver steatosis in germ-free mice following hypercaloric diets. Eur J Nutr. 2019 Aug;58(5):1933-1945. doi: 10.1007/s00394-018-1748-4. Epub 2018 Jun 20.</citation>
    <PMID>29926176</PMID>
  </reference>
  <reference>
    <citation>De Minicis S, Rychlicki C, Agostinelli L, Saccomanno S, Candelaresi C, Trozzi L, Mingarelli E, Facinelli B, Magi G, Palmieri C, Marzioni M, Benedetti A, Svegliati-Baroni G. Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice. Hepatology. 2014 May;59(5):1738-49. doi: 10.1002/hep.26695. Epub 2014 Feb 25.</citation>
    <PMID>23959503</PMID>
  </reference>
  <reference>
    <citation>Kang DJ, Betrapally NS, Ghosh SA, Sartor RB, Hylemon PB, Gillevet PM, Sanyal AJ, Heuman DM, Carl D, Zhou H, Liu R, Wang X, Yang J, Jiao C, Herzog J, Lippman HR, Sikaroodi M, Brown RR, Bajaj JS. Gut microbiota drive the development of neuroinflammatory response in cirrhosis in mice. Hepatology. 2016 Oct;64(4):1232-48. doi: 10.1002/hep.28696. Epub 2016 Jul 29.</citation>
    <PMID>27339732</PMID>
  </reference>
  <reference>
    <citation>Mazagova M, Wang L, Anfora AT, Wissmueller M, Lesley SA, Miyamoto Y, Eckmann L, Dhungana S, Pathmasiri W, Sumner S, Westwater C, Brenner DA, Schnabl B. Commensal microbiota is hepatoprotective and prevents liver fibrosis in mice. FASEB J. 2015 Mar;29(3):1043-55. doi: 10.1096/fj.14-259515. Epub 2014 Dec 2.</citation>
    <PMID>25466902</PMID>
  </reference>
  <reference>
    <citation>Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012 Feb 1;482(7384):179-85. doi: 10.1038/nature10809.</citation>
    <PMID>22297845</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>April 11, 2019</study_first_submitted>
  <study_first_submitted_qc>April 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 16, 2019</study_first_posted>
  <last_update_submitted>September 9, 2019</last_update_submitted>
  <last_update_submitted_qc>September 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inulin</keyword>
  <keyword>microbiome</keyword>
  <keyword>hepatic steatosis</keyword>
  <keyword>obesity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

